Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among Patients with NSCLC and the Risk of Death From Any Cause Among Patients with Solid Tumours By Ogkologos - May 7, 2025 538 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the analysis of TRACERx and MSK-IMPACT studies Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Blinatumomab Improves Survival in Children with Relapsed Leukemia April 1, 2021 Lisocabtagene Maraleucel in Relapsed or Refractory Large B-cell Lymphomas September 7, 2020 Breast Cancer Survivor’s Family Designs a Holiday Light Show in Her... December 15, 2020 Living with a stoma: Neil and Lindsay share their experiences after... July 18, 2022 Load more HOT NEWS Liquid Biopsies on the Horizon for Children with Solid Cancers Adding Cadonilimab to First-Line Standard Chemotherapy Significantly Improves PFS and OS... EMA Recommends Granting a Marketing Authorisation for Plerixafor Accord Mom Diagnosed With Breast Cancer Adopts Healthy Lifestyle To Reinvent Her...
